Kura Oncology Inc (KURA)

NASDAQ
Currency in USD
8.82
-0.23(-2.54%)
Closed
After Hours
8.80-0.02(-0.23%)
KURA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
Fair Value
Day's Range
7.559.14
52 wk Range
6.9824.17
Key Statistics
Edit
Prev. Close
8.82
Open
8.15
Day's Range
7.55-9.14
52 wk Range
6.98-24.17
Volume
6.27M
Average Volume (3m)
2.13M
1-Year Change
-56.68%
Book Value / Share
5.53
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KURA Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Kura Oncology Inc Company Profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology Inc SWOT Analysis


Ziftomenib's Promise
Explore Kura Oncology's lead candidate ziftomenib, showing potential in acute myeloid leukemia treatment with pivotal trial results expected in Q1 2025
Financial Fortitude
Delve into Kura's robust financial position, with cash reserves exceeding $450 million and a strategic partnership with Kyowa Kirin bolstering resources
Market Dynamics
Analyst price targets range from $32 to $37, reflecting optimism about Kura's potential in the competitive AML treatment landscape
Risk vs. Reward
Learn about the challenges Kura faces, including clinical trial outcomes and regulatory hurdles, balanced against the potential for ziftomenib to become best-in-class
Read full SWOT analysis

Kura Oncology Inc Earnings Call Summary for Q3/2024

  • Ziftomenib shows promise in AML treatment; pivotal studies to start mid-2024, NDA filing expected late 2024
  • Q3 2024: R&D expenses up to $41.7M, net loss increased to $54.4M; cash reserves of $455.3M to fund operations into 2027
  • Positive safety profile and activity in combination therapies observed in Phase 1a trials of ziftomenib
  • Preliminary data from various trials to be presented at ASH in December 2024 and early 2025
  • Company advancing trials for other therapies, including KO-2806 and tipifarnib; plans for next-gen menin inhibitor for diabetes
Last Updated: 11/11/2024, 09:02 pm
Read Full Transcript

Compare KURA to Peers and Sector

Metrics to compare
KURA
Peers
Sector
Relationship
P/E Ratio
−3.5x−3.4x−0.6x
PEG Ratio
0.210.060.00
Price/Book
1.6x1.8x2.6x
Price / LTM Sales
-414.1x3.1x
Upside (Analyst Target)
214.9%275.0%48.8%
Fair Value Upside
Unlock22.4%7.5%Unlock

Earnings

Latest Release
Nov 07, 2024
EPS / Forecast
-0.63 / -0.63
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

10.35
CGEM
+0.49%
23.96
IDYA
-4.54%
3.31
IBRX
+3.76%
1.460
HOLO
0.00%
0.684
MRSN
-4.18%

FAQ

What Is the Kura Oncology Inc (KURA) Stock Price Today?

The Kura Oncology Inc stock price today is 8.82

What Stock Exchange Does Kura Oncology Inc Trade On?

Kura Oncology Inc is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Kura Oncology Inc?

The stock symbol for Kura Oncology Inc is "KURA."

What Is the Kura Oncology Inc Market Cap?

As of today, Kura Oncology Inc market cap is 685.88M.

What is Kura Oncology Inc Earnings Per Share?

The Kura Oncology Inc EPS is -2.36.

What Is the Next Kura Oncology Inc Earnings Date?

Kura Oncology Inc will release its next earnings report on 19 Feb 2025.

From a Technical Analysis Perspective, Is KURA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.